<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348998</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000480370</org_study_id>
    <secondary_id>BRIVMRC-3031500</secondary_id>
    <secondary_id>GENENTECH-AVF3549s</secondary_id>
    <nct_id>NCT00348998</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer</brief_title>
  <official_title>Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Mason Hospital/Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Androgens can cause the growth of&#xD;
      prostate cancer cells. Drugs, such as goserelin and bicalutamide, may stop the adrenal glands&#xD;
      from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Bevacizumab may also make tumor cells more sensitive to radiation therapy. Giving bevacizumab&#xD;
      together with hormone therapy and radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bevacizumab together with hormone&#xD;
      therapy and radiation therapy works in treating patients with high-risk locally advanced&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and efficacy of giving bevacizumab together with hormonal therapy&#xD;
           and radiotherapy in patients with high-risk locally advanced prostate cancer.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
      Beginning in week 1, patients receive goserelin subcutaneously once every 3 months for 2&#xD;
      years. Patients also receive oral bicalutamide once daily and bevacizumab IV over 30- to&#xD;
      90-minutes once every 2 weeks in weeks 1-16 and undergo radiotherapy 5 days a week in weeks&#xD;
      9-16. After completion of radiotherapy, patients receive a higher dose of bevacizumab once&#xD;
      every 3 weeks in weeks 17-28.&#xD;
&#xD;
      After completion of study treatment, patients are evaluated at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  High-risk, locally advanced disease (T2b-T4 disease), meeting 1 of the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Gleason score 8-10&#xD;
&#xD;
                    -  Prostate-specific antigen &gt; 20 ng/dL AND Gleason score 7&#xD;
&#xD;
                         -  T2a disease allowed provided ≥ 5 biopsies contain Gleason score 4 +3&#xD;
                            cancer (minimum of 10 biopsies total required)&#xD;
&#xD;
          -  No evidence of metastatic disease within the past 60 days by physical examination,&#xD;
             chest x-ray, bone scan, and CT scan of abdomen and pelvis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Blood pressure ≤ 150/100 mm Hg&#xD;
&#xD;
          -  No cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
               -  History of myocardial infarction within the past 6 months&#xD;
&#xD;
               -  History of stroke within the past 6 months&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  No prior hormonal therapy (except finasteride for obstructive voiding symptoms) for&#xD;
             prostate cancer&#xD;
&#xD;
          -  No prior or concurrent chemotherapy, biologic therapy, or radiotherapy for prostate&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline Vuky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia Mason Hospital/Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 2010 Sep;7(9):494-509. doi: 10.1038/nrurol.2010.134. Review.</citation>
    <PMID>20818327</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

